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IntroductIon
Hemophilia A is a rare congenital bleeding disorder caused by a reduced or absent produc-
tion of clotting factor VIII (FVIII). It is characterized by bleeding episodes predominantly 
into the joints, muscles and soft tissues, which can occur spontaneously or following minor 
trauma [1,2]. The treatment of hemophilia A is a replacement therapy based on the intrave-
nous administration of the deficient factor concentrate (FVIII), which can be used on-demand 
(i.e. from when the bleed occurs until its resolution) or under a prophylaxis regimen (i.e. 
administered at regular intervals, even in the absence of bleed, to prevent its onset) [3]. To 
date, the efficacy of prophylaxis compared to on-demand treatment in preventing joint dam-
age and reducing the progression of hemophilic arthropathy is widely recognized and, for this 
reason, it represents the gold standard of treatment in children born with severe hemophilia A. 
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AbstrAct
INTRODUCTION: Hemophilia A is a rare congenital bleeding disorder caused by a deficiency of clotting factor VIII 
(FVIII). The severe form of the disease is characterized by spontaneous bleeds, especially into the joints. Prophylaxis, 
based on regularly intravenous administration of the missing factor to avoid hemorrhages, represents the gold standard 
of treatment. In recent years, new products that significantly improve the treatment management options for patients with 
hemophilia have become available in the market.
OBJECTIVE: To critically evaluate the pivotal studies of recombinant FVIII (rFVIII) products, approved in Europe within 
the first half of 2018 having obtained the indication for a prophylaxis dosing regimen based also on a twice weekly infusion 
frequency or even less, highlighting their limitations or strengths.
METHODS: A systematic literature search was conducted, and several databases (PubMed and Embase) were consulted.
RESULTS: Nine clinical trials involving patients with severe hemophilia A without inhibitor were included in this analysis. 
Four rFVIII products (Elocta®, Biogen, Cambridge, MA, USA; Kovaltry®, Bayer HealthCare Pharmaceuticals, Germany; 
Afstyla®, CSL Behring GmbH, Germany; Adynovi®, Baxalta Innovation GmbH, Austria) with different pharmacokinetic 
profiles were evaluated. The trials included in this analysis had different designs and heterogeneous methods were utilized 
to assess the study outcomes. The baseline characteristics of the patients enrolled in the studies were also often different 
and sometimes not adequately described. LEOPOLD II, a trial to compare prophylaxis to on-demand therapy with an un-
modified rFVIII product (Kovaltry®, octocog alfa), was the only completely randomized trial that enrolled a more critical 
patient population in terms of compromised joint condition than the other studies. Based on these side-by-side compari-
son, Octocog alfa reported similar efficacy, in terms of annualized bleeding rate, to the other rFVIII products, including 
extended half-life.
CONCLUSIONS: Even without structural modifications, octocog alfa may be considered a useful treatment option for two 
times a week prophylaxis in a selected population of haemophilia patients.
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Due to the short half-life of FVIII of approximately 10-12 hours, prophylaxis usually requires 
intravenous administrations every other day or three times a week [4-6], thereby representing 
a significant burden for patients. In recent years, several products have been developed that 
have significantly improved the treatment management of the patients with hemophilia and 
allowed clinicians to use a personalized therapeutic approach, adjusted for the patients charac-
teristics and attitudes and able to meet their needs. These products, realized through molecular 
structure modifications (e.g. fusion with the Immunoglobulin Fc fragment, PEGylation and 
the creation of a single chain) or innovative production techniques (e.g. the co-expression of 
the Human Heat Shock Protein 70, HSP70), show an improved pharmacokinetic profile which 
have allowed, in some cases, a reduction in the number of prophylaxis infusions required or 
to provide more effective protection from bleed while leaving the frequency of administration 
unchanged [7]. While improved pharmacokinetic properties represent an important advance 
in the management of hemophilia A patients, they remain secondary to clinical efficacy [8], 
but represent an additional “piece of the puzzle” to individualize prophylaxis based on the 
characteristics of the drug and the individual patient’s disease course (bleeding phenotype, 
presence/absence of joint damage, level of physical activity and adherence to prescribed 
treatment). This individualized therapeutic approach, together with the rationalization of con-
sumption and the optimization of outcomes for each patient, is becoming one of the most 
important elements to consider for an appropriate treatment [9,10].
Despite the availability of new recombinant FVIII (rFVIII) products, there are no head-to-
head studies directly comparing the clinical efficacy of the different products. Clinicians can 
guide their choices only with the indirect comparison between drugs, which can be performed 
through a critical evaluation of the individual pivotal trials, in order to understand their value, 
main features, and differences [11].
In the present work, a critical evaluation was carried out of the pivotal studies of the rFVIII 
products approved in Europe within the first half of 2018 which, due to their clinical efficacy 
and improved pharmacokinetic profile, obtained an indication for a prophylaxis dosing regi-
men also including a twice weekly infusion schedule, or even less. The aim of this analysis 
was to critically evaluate the methods and results of the clinical studies, highlighting any 
limitations or strengths.
Methods
Pivotal studies of rFVIII products were identified through a systematic literature search, 
performed on two bibliographic databases (PubMed and Embase). Studies not published in 
English language were excluded from the evaluation. The analysis included only the full-texts 
of the pivotal studies concerning rFVIII products approved in Europe within the first half of 
2018 for the treatment and prevention of hemorrhages in patients with hemophilia A, with pro-
phylaxis regimens based on twice weekly infusions, or less. From each study, the following 
data were extracted: the baseline characteristics of the enrolled population (age, proportion of 
patients with target joints, proportion of patients on prophylaxis before the study enrollment 
and number of bleeds in the 12 months prior to enrollment), the clinical efficacy results (an-
nualized bleeding rate – ABR, number of bleeds and proportion of patients with zero bleeds), 
and the consumption data for the most representative therapeutic regimens approved in Eu-
rope (mean and/or median weekly and annual 
dose). The results of the selected studies were 
critically evaluated, extracted and compared.
results
The pivotal studies of efmoroctocog alfa 
(Elocta®, Biogen, Cambridge, MA, USA) 
[12,13], octocog alfa (Kovaltry®, Bayer 
HealthCare Pharmaceuticals, Germany) [14-
16], lonoctocog alfa (Afstyla®, CSL Behring 
GmbH, Germany) [17,18] and rurioctocog 
alfa pegol (Adynovi®, Baxalta Innovation 
GmbH, Austria) [19,20] were analyzed. Co-
herent with literature evidences [21], ef-
moroctocog alfa and rurioctocog alfa pegol 
were defined as extended half-life (EHL) rF-
VIII products, while octocog alfa and lonoctocog alfa were considered as standard half-life 
(SHL) rFVIII products. A total of nine clinical studies conducted in adolescent/adult (≥12 
years) and pediatric (<12 years) patients with severe hemophilia A without inhibitor were 
evaluated (Table I). Five studies enrolled patients aged ≥12 [12,14,15,17,19], and four studies 
patients aged <12 [13,16,18,20].
Population aged ≥12
The efficacy of efmoroctocog alfa was evaluated in a phase III, open-label, partially ran-
domized clinical trial (A-LONG) [12], which compared on-demand treatment with two pro-
phylactic treatment regimens (an individualized regimen and a weekly regimen). A total of 
142 patients received prophylaxis treatment: 118 were assigned to the individualized arm, 
with an infusion scheme that consisted of the administration of 25 IU/kg on Day 1 and 50 
IU/kg on Day 4, followed by 25-65 IU/kg every 3-5 days, based on individual needs and the 
doctor’s judgment. Only 24 patients were assigned to the weekly arm, which provided for an 
infusion of 65 IU/kg once a week. At the end of the study, patients in the individualized arm 
reported a mean infusion interval of 3.9 days: 29.9% of patients received prophylaxis twice a 
week, 33.3% of patients received an infusion every three days, 3.4% every four days and the 
remaining 33.3% every five days [12].
The efficacy of octocog alfa was evaluated in two clinical studies: LEOPOLD I [14] and 
LEOPOLD II [15]. LEOPOLD I [14] was a phase III, open-label study, which enrolled 62 
patients. All patients included in the study were treated on prophylaxis with 20-50 IU/kg of 
octocog alfa, two (n=18) or three times (n=44) per week, at the discretion of the physician, 
and were followed prospectively for one year. LEOPOLD II [15] was a phase II/III, open-
label, randomized study, with a 12-month follow-up, which enrolled 80 patients: 21 received 
an on-demand treatment and 59 were randomized to receive prophylaxis with 20-30 IU/kg of 
octocog alfa twice a week (n=28), or 30-40 IU/kg three times a week (n=31).
The efficacy of lonoctocog alfa was evaluated in the AFFINITY study [17], a phase II/
III, open-label study which enrolled 173 patients: 146 underwent a prophylaxis with different 
infusion regimens, based on the administration of 20-40 IU/kg of lonoctocog alfa every other 
day (n=9) or 20-50 IU/kg two (n=47) or three (n=79) times per week or other regimens (n=11) 
established at the discretion of the investigator. The remaining part of the sample (n=27/173) 
received on-demand treatment.
The efficacy of rurioctocog alfa pegol was evaluated in the PROLONG-ATE study [19], 
a phase II/III, open-label study which enrolled 137 patients, of whom 120 were treated on 
prophylaxis, with a fixed scheme of 45±5 IU/kg twice a week, and 17 received on-demand 
treatment.
Overall, the studies involved a sample of 530 adolescent/adult patients (≥12 years of age) 
with severe hemophilia A, treated on prophylaxis. The sample size of the individual studies 
was rather heterogeneous, ranging from a minimum of 59 to a maximum of 146 patients 
[15,17]. The most relevant limitation of the selected studies lies in the experimental trials de-
sign, since only the LEOPOLD II study [15] was a completely randomized trial. The baseline 
characteristics of the patients who received prophylaxis are very different between the studies 
(Table II and Table III): the number of patients on prophylaxis prior to study entry and the 
proportion of patients with target joints were very variable. In the LEOPOLD II study [15], 
no patient had received a regular prophylaxis for more than six consecutive months in the five 
years prior to enrollment, while in the PROLONG-ATE study [19], 82.5% of patients were 
already on prophylaxis before enrollment. In the LEOPOLD II study [15], a higher prevalence 
of target joints than in other studies was reported at baseline (89.3% and 90.3% of the patients 
treated with two or three infusions per week, respectively, vs 65.0% of the patients treated 
twice a week in the PROLONG-ATE study) [19]. Further details, such as the mean number of 
total and joint bleeds in the 12 months prior to enrollment, were reported only for LEOPOLD 
I and II [14, 15] (Table III). However, all studies have utilized ABR as the primary efficacy 
outcome, although the methods used for its calculation were very heterogeneous. Almost all 
of the studies reported the median value for the ABR assessment (Table IV). However, the 
studies included in this evaluation are often characterized by a relatively low sample size 
and a follow-up of less than one year; only in the LEOPOLD studies (I and II) [14,15] the 
follow-up lasted 12 months. To overcome these methodological limitations, specific proba-
bilistic models were used in the other studies for the evaluation of the ABR, including the 
negative binomial model and the Poisson model. In the A-LONG study [12], patients treated 
with efmoroctocog alfa in the individualized or weekly prophylaxis arm reported an ABR 
obtained with a negative binomial model of 2.9 (95% CI: 2.3-3.7) and 8.9 (95% CI: 5.5-14.5), 
Product Drug Pivotal study
Studies conducted on cohorts of subjects aged ≥12
Elocta® Efmoroctocog alfa A-LONG [12]
Kovaltry® Octocog alfa LEOPOLD I; LEOPOLD II 
[14,15]
Afstyla® Lonoctocog alfa AFFINITY [17]
Adynovi® Rurioctocog alfa pegol PROLONG-ATE [19]
Studies conducted on cohorts of subjects aged <12
Elocta® Efmoroctocog alfa A-LONG KIDS [13]
Kovaltry® Octocog alfa LEOPOLD KIDS [16]
Afstyla® Lonoctocog alfa AFFINITY KIDS [18]
Adynovi® Rurioctocog alfa pegol PROLONG-ATE KIDS [20]
Table I. Overview of the analyzed studies
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VIII products, while octocog alfa and lonoctocog alfa were considered as standard half-life 
(SHL) rFVIII products. A total of nine clinical studies conducted in adolescent/adult (≥12 
years) and pediatric (<12 years) patients with severe hemophilia A without inhibitor were 
evaluated (Table I). Five studies enrolled patients aged ≥12 [12,14,15,17,19], and four studies 
patients aged <12 [13,16,18,20].
Population aged ≥12
The efficacy of efmoroctocog alfa was evaluated in a phase III, open-label, partially ran-
domized clinical trial (A-LONG) [12], which compared on-demand treatment with two pro-
phylactic treatment regimens (an individualized regimen and a weekly regimen). A total of 
142 patients received prophylaxis treatment: 118 were assigned to the individualized arm, 
with an infusion scheme that consisted of the administration of 25 IU/kg on Day 1 and 50 
IU/kg on Day 4, followed by 25-65 IU/kg every 3-5 days, based on individual needs and the 
doctor’s judgment. Only 24 patients were assigned to the weekly arm, which provided for an 
infusion of 65 IU/kg once a week. At the end of the study, patients in the individualized arm 
reported a mean infusion interval of 3.9 days: 29.9% of patients received prophylaxis twice a 
week, 33.3% of patients received an infusion every three days, 3.4% every four days and the 
remaining 33.3% every five days [12].
The efficacy of octocog alfa was evaluated in two clinical studies: LEOPOLD I [14] and 
LEOPOLD II [15]. LEOPOLD I [14] was a phase III, open-label study, which enrolled 62 
patients. All patients included in the study were treated on prophylaxis with 20-50 IU/kg of 
octocog alfa, two (n=18) or three times (n=44) per week, at the discretion of the physician, 
and were followed prospectively for one year. LEOPOLD II [15] was a phase II/III, open-
label, randomized study, with a 12-month follow-up, which enrolled 80 patients: 21 received 
an on-demand treatment and 59 were randomized to receive prophylaxis with 20-30 IU/kg of 
octocog alfa twice a week (n=28), or 30-40 IU/kg three times a week (n=31).
The efficacy of lonoctocog alfa was evaluated in the AFFINITY study [17], a phase II/
III, open-label study which enrolled 173 patients: 146 underwent a prophylaxis with different 
infusion regimens, based on the administration of 20-40 IU/kg of lonoctocog alfa every other 
day (n=9) or 20-50 IU/kg two (n=47) or three (n=79) times per week or other regimens (n=11) 
established at the discretion of the investigator. The remaining part of the sample (n=27/173) 
received on-demand treatment.
The efficacy of rurioctocog alfa pegol was evaluated in the PROLONG-ATE study [19], 
a phase II/III, open-label study which enrolled 137 patients, of whom 120 were treated on 
prophylaxis, with a fixed scheme of 45±5 IU/kg twice a week, and 17 received on-demand 
treatment.
Overall, the studies involved a sample of 530 adolescent/adult patients (≥12 years of age) 
with severe hemophilia A, treated on prophylaxis. The sample size of the individual studies 
was rather heterogeneous, ranging from a minimum of 59 to a maximum of 146 patients 
[15,17]. The most relevant limitation of the selected studies lies in the experimental trials de-
sign, since only the LEOPOLD II study [15] was a completely randomized trial. The baseline 
characteristics of the patients who received prophylaxis are very different between the studies 
(Table II and Table III): the number of patients on prophylaxis prior to study entry and the 
proportion of patients with target joints were very variable. In the LEOPOLD II study [15], 
no patient had received a regular prophylaxis for more than six consecutive months in the five 
years prior to enrollment, while in the PROLONG-ATE study [19], 82.5% of patients were 
already on prophylaxis before enrollment. In the LEOPOLD II study [15], a higher prevalence 
of target joints than in other studies was reported at baseline (89.3% and 90.3% of the patients 
treated with two or three infusions per week, respectively, vs 65.0% of the patients treated 
twice a week in the PROLONG-ATE study) [19]. Further details, such as the mean number of 
total and joint bleeds in the 12 months prior to enrollment, were reported only for LEOPOLD 
I and II [14, 15] (Table III). However, all studies have utilized ABR as the primary efficacy 
outcome, although the methods used for its calculation were very heterogeneous. Almost all 
of the studies reported the median value for the ABR assessment (Table IV). However, the 
studies included in this evaluation are often characterized by a relatively low sample size 
and a follow-up of less than one year; only in the LEOPOLD studies (I and II) [14,15] the 
follow-up lasted 12 months. To overcome these methodological limitations, specific proba-
bilistic models were used in the other studies for the evaluation of the ABR, including the 
negative binomial model and the Poisson model. In the A-LONG study [12], patients treated 
with efmoroctocog alfa in the individualized or weekly prophylaxis arm reported an ABR 
obtained with a negative binomial model of 2.9 (95% CI: 2.3-3.7) and 8.9 (95% CI: 5.5-14.5), 
Product Drug Pivotal study
Studies conducted on cohorts of subjects aged ≥12
Elocta® Efmoroctocog alfa A-LONG [12]
Kovaltry® Octocog alfa LEOPOLD I; LEOPOLD II 
[14,15]
Afstyla® Lonoctocog alfa AFFINITY [17]
Adynovi® Rurioctocog alfa pegol PROLONG-ATE [19]
Studies conducted on cohorts of subjects aged <12
Elocta® Efmoroctocog alfa A-LONG KIDS [13]
Kovaltry® Octocog alfa LEOPOLD KIDS [16]
Afstyla® Lonoctocog alfa AFFINITY KIDS [18]
Adynovi® Rurioctocog alfa pegol PROLONG-ATE KIDS [20]
Table I. Overview of the analyzed studies
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respectively (Table IV). In the AFFINITY study [17], the ABR was calculated using a Poisson 
probabilistic model, also defined as an approximation of the binomial distribution, and, taking 
into account all the patients treated on prophylaxis, it resulted equal to 2.6 (95% CI: 2.3-2.9). 
In the PROLONG-ATE study [19], a median ABR of 1.9 (IQR: 0.0, 5.8) was reported for 
the patients on prophylaxis, and no probabilistic model was used, although the duration of 
the study was less than one year. In the LEOPOLD I and LEOPOLD II studies [14,15], the 
median ABR referred to all the patients on prophylaxis was 1.0 (IQR: 0.0, 5.1) and 2.0 (IQR: 
0.0, 7.0), respectively.
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The mean weekly or annual FVIII consumption during prophylaxis was reported in all 
studies. Only the PROLONG-ATE study [19] reported the data as a median, which, not neces-
sarily taking into account the dosage distribution per single patient, could represent an under-
estimation (Table V). The consumption and efficacy data (ABR) of the four rFVIII products 
included in this analysis were correlated on a dispersion diagram (Figure 1) and distinguished, 
on the basis of their pharmacokinetic profiles, in EHL products (efmoroctocog alfa and rurioc-
tocog alfa pegol) and SHL products (octocog alfa and lonoctocog alfa) [21]. Depending on the 
sample size to which the estimates refer, each product was associated with an indicator whose 
dimensions are directly proportional to the number of patients enrolled in the study. For each 
study analyzed, the total ABR was reported, referred to all the patients on prophylaxis, regard-
less of the infusion regimen. Since the overall data was not reported in the A-LONG study 
[12], the data of the numerically larger sample of patients, related to individualized prophy-
laxis, had to be used for this study only. Figure 1 does not show any relationship between 
ABR and weekly consumption (R2=0.16). Furthermore, although the differences between the 
pharmacokinetic profiles and the dosing regimens, among the four rFVIII products included 
in the present analysis there was no significant variability regarding the results, neither in 
terms of ABR, nor of consumption (Table IV and Table V).
Population aged <12
The efficacy of efmoroctocog alfa, octocog alfa, lonoctocog alfa and rurioctocog alfa 
pegol for the prophylaxis of children with severe hemophilia A without inhibitor was evalu-
ated in four clinical studies: A-LONG KIDS [13], LEOPOLD KIDS [16], AFFINITY KIDS 
[18] and PROLONG-ATE KIDS [20]. All studies had an open-label design.
The efficacy of efmoroctocog alfa was evaluated in the A-LONG KIDS study [13]. All the 
enrolled patients (n=71) received a twice-weekly prophylaxis, based on the administration of 
25 IU/kg on Day 1 and 50 IU/kg on Day 4, with the possibility of adjusting the dosage up to a 
maximum of 80 IU/kg every other day. The LEOPOLD KIDS study [16] enrolled 51 patients, 
who were treated with 20-50 IU/kg of octocog alfa at least twice a week; 41.2% of patients 
received two infusions per week, 43.1% three infusions per week, and only 15.7% of patients 
received more than three infusions per week. In the AFFINITY KIDS study [18], 81 patients 
received prophylaxis with 15-50 IU/kg of lonoctocog alfa, every other day or two-three times 
Figure 1. Results – Consumptions and ABR (subjects aged ≥12)
Note: the dimension of the indicator is directly proportional to the number of subjects enrolled in the study
29Farmeconomia. Health economics and therapeutic pathways 2020; 21(1)
M. N. D. Di Minno, L. S. D’Angiolella, P. A. Cortesi, A. C. Molinari, L. G. Mantovani
per week, at the discretion of the clinician and depending on the characteristics of each pa-
tient; 53.1% of the patients on prophylaxis received the treatment twice a week, 30.9% three 
times per week and the remaining 16.0% every other day or according to other regimens. In 
the PROLONG-ATE KIDS study [20], which assessed the efficacy of rurioctocog alfa pegol, 
66 patients received twice-weekly prophylaxis, at a dosage of 40-60 IU/kg.
The sample size was well balanced between the studies. With regard to the baseline char-
acteristics, a lower proportion of patients already on prophylaxis before the enrollment was re-
ported in the studies LEOPOLD KIDS and AFFINITY KIDS [16,18] (Table VI). An adequate 
and detailed description of the baseline orthopedic status was often not provided, although it 
is an important predictor of outcome, especially when dealing with pediatric patients. Table 
VII reports the lack of information about the joint status of the patients involved in the vari-
ous studies. LEOPOLD KIDS [16] is the most complete study in terms of information on the 
clinical characteristics of the patients enrolled. The proportion of patients with target joints 
is higher in LEOPOLD KIDS [16] than in the other studies [13,20]. In the AFFINITY KIDS 
Study A-lOng KIDS leOPOlD KIDS AFFInITY KIDS
PROlOng-ATe 
KIDS
Drug Efmoroctocog alfa Octocog alfa Lonoctocog alfa Rurioctocog alfa pegol
Regimen Prophylaxis Prophylaxis Prophylaxis Prophylaxis
Frequency of 
administration
- 2 times per 
week
>2 times 
per week
2 times per 
week
>2 times 
per week
-
Patients with target 
joints, %
18.3% 27.5% NR 21.2%
NR NR
Bleeds in last 12 
months, median (IQR), 
n
2.0 (0-36) 4.0 (0-55)a NR NR
Joint bleeds in last 
12 months, median 
(range), n
8.0 (1.0-28.0) (TJ) – 2.0 
(0.0-36.0) (no TJ)
0.0 (0-33) NR NR
Table VII. Baseline orthopedic status (subjects aged <12)
NR = not reported
a 1 (0-55) in subjects who received prophylaxis before enrollment, 10 (4-49) in subjects treated on-demand before enrollment
Study A-lOng KIDS leOPOlD KIDS AFFInITY KIDS
PROlOng-ATe 
KIDS
Drug Efmoroctocog alfa Octocog alfa Lonoctocog alfa Rurioctocog alfa pegol
Regimen Prophylaxis Prophylaxis Prophylaxis Prophylaxis
Frequency of 
administration
- 2 times per 
week
>2 times 
per week
2 times per 
week
>2 times 
per week
-
Study design Open-label
(not randomized)
Open-label
(not randomized)
Open-label
(not randomized)
Open-label
(not randomized)
Subjects, n 71 51 81a 66
21 30 43 38
Age, median (range), 
years
5.0 (1-11) 6.0 (1-11) 7.0 (1-11)b 6.0 (1-11)
NR
Age, mean (SD), years NR 6.4 (3) NR 6.0 (2.7)
NR NR
Patients in prophylaxis 
before enrollment, %
88.7c 78.40d 71.4be 92.4f
Table VI. Baseline characteristics (subjects aged <12)
NR = not reported
a Sample includes 84 subjects (3 received on-demand treatment and 81 prophylaxis). Among patients on prophylaxis, 65 achieved ≥50 exposure days and 
1 patient was excluded due to inhibitor development
b The data refers to all subjects, including those in the on-demand regimen (n=3)
c Before enrollment, 88.7% and 11.3% of subjects received prophylaxis and on-demand treatment, respectively
d Before enrollment, 78.4% and 21.6% of subjects received prophylaxis and on-demand treatment, respectively
e Before enrollment, 71.4% and 28.6% of subjects received prophylaxis and on-demand treatment, respectively
f Before enrollment, 92.4% and 7.6% of subjects received prophylaxis and on-demand treatment, respectively
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study [18], no information was provided on the joint status of the patients at baseline. The 
number of bleeds in the 12 months prior to enrollment was higher in LEOPOLD KIDS than 
in A-LONG KIDS. The duration of follow-up in the patients receiving prophylaxis was ap-
proximately 6 months for all studies (Table VIII).
The median ABR was the primary clinical efficacy outcome in all studies. Only in the 
PROLONG-ATE KIDS study [20], the ABR was reported as an estimate, obtained using a 
negative binomial model (Table VIII). The patients in the LEOPOLD KIDS [16] and AFFIN-
ITY KIDS [18] studies reported the lowest (1.9, IQR: 0.0-6.0) and highest (3.7, IQR: 0.0-7.2) 
median ABR, respectively (Table VIII).
In terms of consumption, the reported median weekly dose for the various rFVIII products 
ranged from 79.0 to 97.5 IU/kg, and did not differ significantly between LEOPOLD KIDS and 
A-LONG KIDS [13,16] (Table IX), despite prophylaxis having different infusion regimens.
Figure 2 shows the relationship between the ABR and weekly consumption attributable 
to each of the rFVIII products included in the analysis, and highlights the absence of a cor-
relation between ABR and consumption of rFVIII (R2= 0.056) also in the pediatric popula-
tion. The median weekly consumption of octocog alfa was higher than lonoctocog alfa and 
efmoroctocog alfa, but lower than rurioctocog alfa pegol [13,16,18,20]. The lowest ABR was 
reported in LEOPOLD KIDS [16], although it did not differ significantly from that attribut-
able to the other rFVIII products.
Study A-lOng KIDS leOPOlD KIDS AFFInITY KIDS PROlOng-ATe KIDS
Drug Efmoroctocog alfa Octocog alfa Lonoctocog alfa Rurioctocog alfa pegol
Regimen Prophylaxis Prophylaxis Prophylaxis Prophylaxis
Frequency of 
administration
- 2 times 
per week
>2 times 
per week
2 times 
per week
>2 times 
per week
-
Follow-up, median 
(range), months
6.1 6.0 (4.5-5.5) 5.6 6.0
NR NR
Bleeds per year, median 
(IQR), n
NR 1.9a (0-6.0) 5.5 (4.8-6.3) NR
NR 6.2  
(5.2-7.4)
5.8  
(4.5-7.4)
ABR, median (IQR) 2.0 (0.0–4.0) 1.9 (0.0-6.0) 3.7 (0.0-7.2) 2.0 (0.0-3.9)
4.4  
(2.3-7.2)
2.3  
(0.0-11.6)
ABR, mean (SD) NR NR NR NR
ABR, negative binomial 
model (95% CI)
NR NR NR 3.0 (2.2-4.2)
Joint bleeds, median 
(IQR), n
0.0 (0.0-0.0)B NR NR NR
Joint bleed, mean (95% 
IC), n 
NR NR 3.3 (2.7-3.9) NR
3.8  
(3.1-4.8)
3.1  
(2.2-4.4)
AJBR, median (IQR) NR NR 1.6 (0.0-4.9) 0.0 (0.0-1.9)
1.9  
(0.0-4.6)
0.8  
(0.0-5.3)
AJBR, negative binomial 
model (95% CI)
NR 0.0 (0.0-2.0)c NR 1.1 (0.6-1.9)
NR NR
Subjects with 0 bleeds, % 46.4 45.1 31.6d 38.0
NR NR NR NR
Table VIII. Results – ABR (subjects aged <12)
NR = not reported
a The data reported in the study is an annualized estimate (follow-up <12) and coincides with the median ABR
b 0.0 (0.0-0.0) spontaneous joint bleeds and 0.0 (0.0-2.0) post-trauma bleeds
c 0.0 (0.0-2.0) joint bleeds and 0.0 (0.0-0.0) spontaneous bleeds
d The data refers only to subjects who did not developed inhibitor before and during the study (n=19). Authors declare that this value is similar to the one 
obtained on all subjects who underwent prophylaxis with lonoctocog alfa during the study
Study A-lOng KIDS leOPOlD KIDS AFFInITY KIDS PROlOng-ATe KIDS
Drug Efmoroctocog-alfa Octocog-alfa Lonoctocog-alfa Rurioctocog-alfa pegol
Regimen Prophylaxis Prophylaxis Prophylaxis Prophylaxis
Frequency of 
administration
- 2 times 
per week
>2 times 
per week
2 times 
per week
>2 times 
per week
-
Dosing regimen “Twice-weekly infusions 
of 25 IU kg-1 on Day 1 
and 50 IU kg-1 on Day 
4. Adjustments in dose 
to a maximum of 80 
IU/Kg”
“25-50 IU Kg-1
≥ 2 times weekly”
“15 to 50 IU kg-1 
every 2nd day or 2-3 
times per week or at 
a dose and frequency 
determined by the 
investigator based on 
historical FVIII dosing 
and available PK data”
“Twice-weekly prophylaxis
(in 3–4 days intervals)
with 40-60 IU kg-1”
Weekly consumption, 
median (range), IU/Kg
88.1 (80.3-103.1)a 90.1 (56.0-154.7) 79.0 97.5
NR
Weekly consumption, 
mean (SD), IU/Kg
NR 93.6 82.7 NR
Annual consumption, 
median (range), IU/Kg
NR NR 4,109.0 NR
Annual consumption, 
mean (SD), IU/Kg
NR 4,867.2 NR NR
Table IX. Results – Consumptions (subjects aged <12)
NR = not reported
a The data refers to subjects in a twice weekly prophylaxis, excluding 2 subjects who had received a variable interval regimen
Figure 2. Results – Consumptions and ABR (subjects aged <12)
Note: the dimension of the indicator is directly proportional to the number of subjects enrolled in the study
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study [18], no information was provided on the joint status of the patients at baseline. The 
number of bleeds in the 12 months prior to enrollment was higher in LEOPOLD KIDS than 
in A-LONG KIDS. The duration of follow-up in the patients receiving prophylaxis was ap-
proximately 6 months for all studies (Table VIII).
The median ABR was the primary clinical efficacy outcome in all studies. Only in the 
PROLONG-ATE KIDS study [20], the ABR was reported as an estimate, obtained using a 
negative binomial model (Table VIII). The patients in the LEOPOLD KIDS [16] and AFFIN-
ITY KIDS [18] studies reported the lowest (1.9, IQR: 0.0-6.0) and highest (3.7, IQR: 0.0-7.2) 
median ABR, respectively (Table VIII).
In terms of consumption, the reported median weekly dose for the various rFVIII products 
ranged from 79.0 to 97.5 IU/kg, and did not differ significantly between LEOPOLD KIDS and 
A-LONG KIDS [13,16] (Table IX), despite prophylaxis having different infusion regimens.
Figure 2 shows the relationship between the ABR and weekly consumption attributable 
to each of the rFVIII products included in the analysis, and highlights the absence of a cor-
relation between ABR and consumption of rFVIII (R2= 0.056) also in the pediatric popula-
tion. The median weekly consumption of octocog alfa was higher than lonoctocog alfa and 
efmoroctocog alfa, but lower than rurioctocog alfa pegol [13,16,18,20]. The lowest ABR was 
reported in LEOPOLD KIDS [16], although it did not differ significantly from that attribut-
able to the other rFVIII products.
Study A-lOng KIDS leOPOlD KIDS AFFInITY KIDS PROlOng-ATe KIDS
Drug Efmoroctocog alfa Octocog alfa Lonoctocog alfa Rurioctocog alfa pegol
Regimen Prophylaxis Prophylaxis Prophylaxis Prophylaxis
Frequency of 
administration
- 2 times 
per week
>2 times 
per week
2 times 
per week
>2 times 
per week
-
Follow-up, median 
(range), months
6.1 6.0 (4.5-5.5) 5.6 6.0
NR NR
Bleeds per year, median 
(IQR), n
NR 1.9a (0-6.0) 5.5 (4.8-6.3) NR
NR 6.2  
(5.2-7.4)
5.8  
(4.5-7.4)
ABR, median (IQR) 2.0 (0.0–4.0) 1.9 (0.0-6.0) 3.7 (0.0-7.2) 2.0 (0.0-3.9)
4.4  
(2.3-7.2)
2.3  
(0.0-11.6)
ABR, mean (SD) NR NR NR NR
ABR, negative binomial 
model (95% CI)
NR NR NR 3.0 (2.2-4.2)
Joint bleeds, median 
(IQR), n
0.0 (0.0-0.0)B NR NR NR
Joint bleed, mean (95% 
IC), n 
NR NR 3.3 (2.7-3.9) NR
3.8  
(3.1-4.8)
3.1  
(2.2-4.4)
AJBR, median (IQR) NR NR 1.6 (0.0-4.9) 0.0 (0.0-1.9)
1.9  
(0.0-4.6)
0.8  
(0.0-5.3)
AJBR, negative binomial 
model (95% CI)
NR 0.0 (0.0-2.0)c NR 1.1 (0.6-1.9)
NR NR
Subjects with 0 bleeds, % 46.4 45.1 31.6d 38.0
NR NR NR NR
Table VIII. Results – ABR (subjects aged <12)
NR = not reported
a The data reported in the study is an annualized estimate (follow-up <12) and coincides with the median ABR
b 0.0 (0.0-0.0) spontaneous joint bleeds and 0.0 (0.0-2.0) post-trauma bleeds
c 0.0 (0.0-2.0) joint bleeds and 0.0 (0.0-0.0) spontaneous bleeds
d The data refers only to subjects who did not developed inhibitor before and during the study (n=19). Authors declare that this value is similar to the one 
obtained on all subjects who underwent prophylaxis with lonoctocog alfa during the study
Study A-lOng KIDS leOPOlD KIDS AFFInITY KIDS PROlOng-ATe KIDS
Drug Efmoroctocog-alfa Octocog-alfa Lonoctocog-alfa Rurioctocog-alfa pegol
Regimen Prophylaxis Prophylaxis Prophylaxis Prophylaxis
Frequency of 
administration
- 2 times 
per week
>2 times 
per week
2 times 
per week
>2 times 
per week
-
Dosing regimen “Twice-weekly infusions 
of 25 IU kg-1 on Day 1 
and 50 IU kg-1 on Day 
4. Adjustments in dose 
to a maximum of 80 
IU/Kg”
“25-50 IU Kg-1
≥ 2 times weekly”
“15 to 50 IU kg-1 
every 2nd day or 2-3 
times per week or at 
a dose and frequency 
determined by the 
investigator based on 
historical FVIII dosing 
and available PK data”
“Twice-weekly prophylaxis
(in 3–4 days intervals)
with 40-60 IU kg-1”
Weekly consumption, 
median (range), IU/Kg
88.1 (80.3-103.1)a 90.1 (56.0-154.7) 79.0 97.5
NR
Weekly consumption, 
mean (SD), IU/Kg
NR 93.6 82.7 NR
Annual consumption, 
median (range), IU/Kg
NR NR 4,109.0 NR
Annual consumption, 
mean (SD), IU/Kg
NR 4,867.2 NR NR
Table IX. Results – Consumptions (subjects aged <12)
NR = not reported
a The data refers to subjects in a twice weekly prophylaxis, excluding 2 subjects who had received a variable interval regimen
Figure 2. Results – Consumptions and ABR (subjects aged <12)
Note: the dimension of the indicator is directly proportional to the number of subjects enrolled in the study
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dIscussIon
Hemophilia A is undergoing an important change in the management and treatment of 
patients. While on one hand new products with promising features are appearing on the hori-
zon, on the other there is a need to have tools by which clinicians can guide their therapeutic 
choices. After over 40 years of clinical experience in the field of hemophilia, prophylaxis is 
now recognized as the only therapeutic approach able to modify the natural course of the dis-
ease, preventing joint damage [7]. New drugs have recently become available, and the extent 
of clinical evidence has grown (and is likely to further increase). Nevertheless, due to the rar-
ity of the disease, it is still complex to conduct head-to-head studies to compare and establish 
superiority of one product over another. Therefore, the critical evaluation of the individual 
trials remains a useful approach for clinicians in order to guide their choices.
This analysis evaluated the pivotal studies of the rFVIII products registered in Europe 
within the first half of 2018 for the treatment and prophylaxis of patients with hemophilia 
A without inhibitor. Compared to a previous paper [3], this analysis included products with 
improved pharmacokinetic profile and a dose regimen based also on a twice weekly schedule, 
and examined the evidence collected among the entire population (pediatric, adolescent and 
adult patients).
Although the knowledge of patients characteristics upon enrollment and an accurate de-
scription of the bleeding phenotype are important clinical predictors to allow a more accurate 
assessment of the outcome and actual clinical benefit, they are often not described in detail in 
the studies, or are even missing. The studies included in this evaluation have different designs, 
with only LEOPOLD II [15] (octocog alfa) being a completely randomized trial. In this last 
study, in fact, the patients were assigned to different treatments in such ways as to exclude 
any type of influence on the part of the investigating physician and the bleeding phenotype. In 
general, randomization ensures that the patients characteristics in the various treatment arms 
are as homogeneous as possible, thereby increasing the likelihood that any potentially con-
founding variables will be distributed uniformly between the groups compared, but requires 
a minimum sample size to produce scientifically reliable results to ensure greater robustness. 
In all of the studies identified, ABR and consumption are significant outcomes, on the basis 
of which doctors and patients should be able to outline an optimal therapy. However, ABR is 
calculated differently in each of the studies [3] and, depending on the duration of the studies, 
the findings are almost always annualized estimates [22]. This, together with the differences 
in the experimental design and the characteristics of the patients enrolled, significantly limit 
the possibility of a direct comparison between the various rFVIII products.
In this analysis, even without structural modifications, octocog alfa showed similar re-
sults, in terms of annualized bleeding rate, to the other rFVIII products, including extended 
half-life. Octocog alfa may be a useful treatment option in the prophylaxis of adult, adolescent 
and pediatric patients with hemophilia A, also in a dose regimen lower than three administra-
tions per week. The efficacy data of octocog alfa are supported by a robust and comprehensive 
clinical program, well detailed in the literature, which involved both adolescent/adult and 
pediatric patients. The results reported in the LEOPOLD studies [14,15] are very promis-
ing, also in relation to the methods defined in the trial. The LEOPOLD II study [15] has a 
randomized experimental design that, in addition to playing an important role in ensuring the 
robustness of the data, minimizes the variables that could affect the results, and which the 
investigating physician would not be able to eliminate. On the other hand, the results of the 
clinical studies of the EHL products did not show any convincing evidence of superiority in 
bleeding reduction of one of the products over the others.
Despite the recent advances in the field of hemophilia, in order to guide doctors towards a 
therapy focused on the patient’s needs and based on solid and comprehensive data, the studies 
should report more detailed and homogeneous information. Further clinical studies should be 
conducted to evaluate and confirm the efficacy of prophylaxis with the various rFVIII prod-
ucts in pediatric, adolescent and adult patients. The characteristics of the patients included in 
the studies, the experimental design, the duration and the methodological approaches used 
to estimate the efficacy outcomes should also be more homogeneous. In fact, the availability 
of studies with similar characteristics would reduce the limits that currently do not allow a 
direct comparison between them. Inevitably, the results of these studies should be integrated 
with real-life studies, which, together with economic assessments, will allow those who are 
responsible for making decisions in the healthcare sector to be better informed, especially in 
such a complex context as hemophilia. Further, other new products (long acting rFVIII, bispe-
cific antibody coupling FX and FIXa, monoclonal antibody against TFPI, siRNA knockdown 
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of AT) have been approved or will be evaluated for the market access in Europe in the near 
future. Our analysis could be used as a reference to assess the trials characteristics and the 
efficacy and consumption data of these new products.
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